electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.
Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.
electroCore, Inc. announced that Donald Melnikoff joined as SVP, Engineering, Regulatory, and Compliance, with an inducement grant of 10,000 RSUs. The RSUs were granted under NASDAQ Listing Rule 5635(c)(4) and will vest over three years.
electroCore, Inc. (Nasdaq: ECOR) will announce its first quarter financial results on May 8, 2024, after the market closes. The company, specializing in bioelectronic medicine and wellness, will hold a conference call to discuss the results and answer questions.
electroCore, Inc. (NASDAQ: ECOR) announced positive results from its recent Truvaga Plus consumer study, showing improvements in sleep, focus, stress, energy, and mood. 82% felt calmer, 82% mentally healthier, 77% more alert, 77% more relaxed, 74% slept better, 74% mood improved, and 67% had more energy. Users reported between 30 mins to 2+ hours of additional sleep per night. 87% expressed interest in continuing the product for ongoing wellness benefits.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.